New hope for rare cancer: experimental drug targets tumor defense
NCT ID NCT03781986
Summary
This study is testing a new oral drug called APG-115 for people with a specific type of advanced salivary gland cancer. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. It involves 41 participants whose cancer has a normal p53 gene and is not suitable for curative surgery or radiation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SALIVARY GLAND CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.